Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program.

Gottlieb, Alice B; Burge, Russel; Malatestinic, William N; Zhu, Baojin; Zhao, Yunyang; McCormack, Julie; Kimel, Miriam; Merola, Joseph F

Gottlieb, Alice B; Burge, Russel; Malatestinic, William N; Zhu, Baojin; Zhao, Yunyang; McCormack, Julie; Kimel, Miriam; Merola, Joseph F.

Afiliación

Gottlieb AB; Icahn School of Medicine at Mount Sinai, New York, NY, USA. alicegottliebderm@gmail.com.
Burge R; Eli Lilly and Company, Indianapolis, IN, USA.
Malatestinic WN; University of Cincinnati, Cincinnati, OH, USA.
Zhu B; Eli Lilly and Company, Indianapolis, IN, USA.
Zhao Y; Eli Lilly and Company, Indianapolis, IN, USA.
McCormack J; Eli Lilly and Company, Indianapolis, IN, USA.
Kimel M; Evidera, Bethesda, MD, USA.
Merola JF; Evidera, Bethesda, MD, USA.

Dermatol Ther (Heidelb) ; 13(8): 1831-1846, 2023 Aug.

Article en En | MEDLINE | ID: mdl-37434099

Palabras clave

Customer support program; Ixekizumab; Patient-reported outcomes; Psoriasis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Evaluation_studies / Observational_studies Idioma: En Revista: Dermatol Ther (Heidelb) Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google